Contrast-MRI superior to PET (positron emission tomography) for liver metastases
This article was originally published in Clinica
Significantly more and smaller liver metastases can be detected using contrast-enhanced MRI than with whole-body FDG (Fluro-D-glucose) positron emission tomography (PET), say researchers from the Massachusetts General Hospital in Boston.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.